Stem cell factor (SCF) and basic fibroblast growth factor (bFGF) are hematopoietic cytokines produced by bone marrow stromal celis. It is known that, although SCF and bFGF have limited clonogenic activity on their own, they can augment colony-stimulating factor (CSF)-mediated progenitor cell growth. Because these factors are both sequestered by stromal cells, we examined their interaction on progenitor cell growth in conjunction with granulocyte-macrophage-CSF (GM-CSF). In this study, we show that clonogenic growth derived from low-density bone marrow cells stimulated by GM-CSF is significantly augmented (P < .001) in the presence of maximal (1 00 ng/mL) concentrations of SCF in combination with 100 ng/mL of bFGF.
TEM CELL FACTOR (SCF) is a hematopoietic and tissue growth factor that serves as the ligand for the c-kit oncogene."6 SCF stimulates little colony growth when used alone, but has been shown to augment the in vitro proliferation of both myeloid and lymphoid hematopoietic progenitor in the presence of erythropoietin, granulocyte colony-stimulating factor (G-CSF), interleukin-3 (IL-3), or granulocyte-macrophage-CSF (GM-CSF). It has been proposed that SCF produced locally at high concentrations by marrow stromal cells acts as an "anchor" factor and permits stem cells to respond to physiologic concentrations of other cytokines."
There is evidence that basic fibroblast growth factor (bFGF) can act as a hematopoietic cytokine. It is produced by12-13 and is a potent mitogen for human stromal cells.14 It is found in megakaryocytes and cells of the granulocyte lineage in vivo, 13 and it enhances megakaryopoiesi~'~,~~ and myelopoiesis in human long-term bone marrow cultures.l' In the presence of bFGF and insulin-like growth factor, single human bone marrow stem cells give rise to the hematopoietic microenvironment as well as hematopoietic progenitor cells.'8 bFGF also augments the proliferation of progenitor cells when added in conjunction with other growth fa~torsl'-~' and it counteracts the suppressive effects of transforming growth factor-@l (TGF-P 1) on human myeloid progenitor cells.'' Recently, FGF receptor genes have been found to be expressed in normal human megakaryocytesZ2 and some leukemic ~e l l s .~~, *~ bFGF and SCF are both stromal cell-derived factors. The combination ofthese two cytokines in conjunction with leukemia inhibitory factor has already been shown to stimulate the long-term proliferation of mouse primordial germ ~e l l s .~~*~~ Because of this synergy in a stem cell population, we investigated whether bFGF and SCF would be synergistic in augmenting GM-CSF-mediated human progenitor cell growth of hematopoietic precursor cells.
MATERIALS AND METHODS

S
Reagents. Recombinant human SCF, recombinant human G-CSF, recombinant human IL-3, and recombinant human GM-CSF were obtained from Amgen (Thousand Oaks, CA). Human GM-CSF and G-CSF have a specific activity of 1 X IO8 U/mg protein in a standard bone marrow colony-forming unit granulocyte-macro- Cell separation techniques. Bone marrow cells were obtained from healthy volunteers after informed consent. The mononuclear cells were isolated by centrifugation on Ficoll-Hypaque gradients (1.077 g/mL; Pharmacia Fine Chemicals, Piscataway, NJ), washed twice in phosphate-buffered saline (PBS), and suspended in Iscove's modified Dulbecco's medium (IMDM) containing 10% fetal calf serum (FCS; Hyclone, Logan, UT) supplemented with penicillin (100 U/mL; GIBCO, Grand Island, NY), streptomycin (100 pg/ mL; GIBCO), and 3 mg/mL glutamine (GIBCO). These cells were used as target cell populations for the CFU-GM progenitor cell assay.
CD34' enriched cell populations were prepared ^as follows. Mononuclear cells were washed twice in PBS and resuspended at 15 X IO6 cells/4 mL in PBS containing 0. I% human gamma globulin and incubated for I5 minutes at room temperature. Four-milliliter suspensions were then transferred to AIS MicroCELLector T-25 flasks coated with soybean agglutinin (Applied Immune Sciences, Menlo Park, CA) to remove soybean agglutinin-positive cells as previously described.*' After I hour of incubation on a nonvibrating surface, supernatant cells were removed. Flasks were then washed three times to remove any residual nonadherent cells. The nonadherent cell population was then washed twice in PBS, resuspended at 15 X IO6 cells/4 mL in PBS containing 0.1% human gamma globulin and incubated for 15 minutes at room temperature. Cell suspensions were subsequently transferred to AIS MicroCELLector T-25 flasks coated with anti-CD34 antibodies (Applied Immune Sciences). Nonadherent cells were removed after 1 hour incubation at room temperature on a nonvibrating surface. Flasks were washed three times to remove any residual nonadherent cells. Ten milliliters of PBS containing 10% FCS was then added to each flask and adherent cells removed by manual agitation of the flasks. The final cell population was found to contain 87% to 97% CD34+ cells, as analyzed by flow cytometry using an FITC-conjugated anti-CD34 antibody, HPCA-I .
CFU-GM. Low-density (1 X IO5 cells/mL) or CD34+ (5 X IO3 cells/mL) were cultured in 35-mm tissue culture dishes (Corning, Corning, NY) in McCoy's modified assay medium containing 0.3% agar (DIFCO, Detroit, MI) and 10% FCS." Cultures were stimulated by the addition of the following growth factor concentrations alone or in combination: 0.1 ng/mL, 1 .0 ng/mL, I O ng/mL, or 20 ng/mL of GM-CSF; 10 ng/mL, 100 ng/mL, or 1,000 ng/mL of bFGF; 1 0 0 ng/mL or 1,000 ng/mL of SCF; 100 ng/mL G-CSF and 1.0 ng/mL, 10 ng/mL, or 100 ng/mL IL-3.
RESULTS
Low-density bone marrow cells were cultured in the presence of GM-CSF, SCF, or bFGF GM-CSF + SCF GM-CSF + bFGF or GM-CSF + SCF + bFGF (Fig I) . No GABRILOVE ET AL growth was observed in the presence of bFGF or SCF alone (Fig 1) . The addition of either SCF (100 ng/mL) or bFGF (100 ng/mL) to cultures stimulated by GM-CSF (20 ng/mL) resulted in a twofold increase in day-7 and day-14 progenitor cell growth (Fig 1) . The addition of both SCF (100 ng/ mL) and bFGF (100 ng/mL) to GM-CSF-treated cultures resulted in a further increase in colony growth ( 1 .7-fold) over that with GM-CSF + SCF or GM-CSF + FGF (Fig 1) .
To determine whether the synergism observed with SCF + bFGF in combination with GM-CSF was direct or indirect, we examined the effect of these growth factors on the proliferation of CD34' cells (Fig 2) . No clonogenic growth was observed when CD34+ cells were stimulated by either SCF or bFGF alone. In the presence of bFGF, a 1.7-fold increase in progenitor cell growth was observed on day 7 of culture (P < .01). When SCF (l00 ng/mL) was added to cultures stimulated by GM-CSF (20 ng/mL), a four-fold (day 7; P < 0.001) and 2.4-fold (day 14; P < .001) increase in the mean number of day-7 clusters and day-l4 colonies was observed. When CD34+ cells were stimulated by GM-CSF (20 ng/mL), SCF ( 100 ng/mL), and bFGF (1 00 ng/mL) in combination, a sevenfold (day 7; P < .001) and 3.6-fold (day 14; P < .001) augmentation in progenitor cell growth was observed, demonstrating the potent synergism of these two growth factors in enhancing GM-CSF-supported progenitor cell growth. No synergistic augmentation of progenitor cell growth was observed when suboptimal concentra- tions (0.1 ng/mL and 1 .O ng/mL) of GM-CSF were used; furthermore, no additional augmentation in clonogenic growth was noted when higher concentrations of bFGF and SCF ( l ,000 ng/mL) were added to cultures stimulated by optimal concentrations of GM-CSF (data not shown). In addition, an increase in the size of colonies and clusters was observed when bFGF, SCF, and GM-CSF were used in combination compared with the size noted when only SCF plus GM-CSF or bFGF plus GM-CSF were combined (data not shown).
Synergistic augmentation of IL-3-stimulated (Table 1) but not G-CSF-stimulated (data not shown) progenitor cell growth was also observed. In this instance, bFGF and SCF increased the number of clusters and colonies stimulated by both optimal and suboptimal concentrations of IL-3 (Table  1 ).
DISCUSSION
In this study, we show that bFGF in combination with optimal concentrations of SCF is synergistic in significantly augmenting GM-CSF-and IL-3-but not G-CSF-mediated myeloid progenitor cell growth. In addition, our data show that this effect is even more pronounced when purified progenitors are used as targets. This latter observation suggests that the induction of other hematopoietic growth factors by accessory cells by bFGF and/or SCF is not likely to be responsible for the enhanced clonogenic growth of CFU-GM.
It is known that optimal proliferation of both early and committed human and murine progenitors requires stimulation by multiple hematopoietic growth factors.",'* SCF, which has little capacity to support progenitor cell growth alone, has been shown to stimulate significantly the growth of hematopoietic colonies. SCF has also been shown to restore the proliferative response of both unfractionated bone marrow, partially and highly purified SCA'Lin-cells to subliminal concentrations of macrophage-CSF, G-CSF, GM-CSF, IL-l, and IL-3." This has led Lowry et all' to propose a model of control of the hematopoietic microenvironment in which SCF at locally high concentrations on the stromal cell surface enables the stem cells to respond to low physiologic concentrations of other cytokines. It is possible that bFGF might have a similar permissive effect to that noted for SCF.
bFGF is detectable in human megakaryocytes, platelets, and myeloid cells in vivot4 and is produced by stromal cells in vitro.I3 In vitro, in human bone marrow cultures, bFGF binds to a cell surface phosphatidylinositol-linked heparan sulfate proteoglycan.12 Heparan sulfate proteoglycans also mediate the attachment of progenitor cells to ~trorna.'~ Thus, it is possible that, within the stromal microenvironment, bFGF might be locally sequestered by heparan sulfate proteoglycans and that bFGF, in conjunction with SCF and other cytokines, might interact with and regulate the proliferation of adjacent hematopoietic stem cells.
